Autem Therapeutics

Autem Therapeutics is a privately held oncology therapeutic and bioelectric company headquartered in Hanover NH, USA that is developing a novel, non-invasive and non-toxic oncology treatment platform targeting HCC (liver cancer) and other solid tumor cancers. The company has received FDA breakthrough designation for its AutEMsys™ therapy for the treatment of advanced HCC patients. The AutEMsys™ therapy delivers personalized, amplitude-modulated electromagnetic (EM) frequencies (and based on initial clinical feasibility studies shows promise in shrinking cancerous tumors, enhancing quality of life and extending survival in early and advanced stage cancer patient populations. Autem Therapeutics anticipates submitting an FDA Investigational Device Exemption (IDE) to initiate FDA pivotal clinical trials in late 2022 or early 2023.